Publications

Publikationen

Filter:
  • Blankart, Katharina E.; Lichtenberg, Frank R.: The Effects of Off-label Drugs Use on Disability and Medical Expenditure. Research, National Bureau Of Economic (Ed.), 2022. Full textCitationDetails
  • Benjamin Birkner MSc, Katharina E. Blankart PhD: The Effect of Biosimilar Prescription Targets for Erythorpoiesis-Stimulating Agents on the Prescribing Behavior of Physicians in Germany. In: Value in Health, Vol 25 (2022) No 9, p. 1528-1538. Full textCitationDetails
  • Blankart, Katharina; Naci, Huseyin; Chandra, Amitabh: Availability of New Medicines in the US and Germany From 2004 to 2018. In: JAMA Network Open, Vol 5 (2022) No 8. Full textCitationDetails
  • Katharina E. Blankart PhD, Stefan Felder PhD: Do Medicine Shortages Reduce Access and Increase Pharmaceutical Expenditure? A Retrospective Analysis of Switzerland 2015-2020. In: Value in Health, Vol 25 (2022) No 7, p. 1124-1132. Full textCitationDetails
  • Blankart; Katharina; Avdic, Daniel: A Hard Look at “Soft” Cost‐control Measures in Healthcare Organizations: Evidence from Preferred Drug Policies in Germany. Series, Cinch Working Paper (Ed.), 2021. doi:10.17185/duepublico/74978Full textCitationDetails
  • Vadia R, Blankart KE.: Regional Innovation Systems of Medical Technology: A knowledge production function of cardiovascular research and funding in Europe - A knowledge production function of cardiovascular research and funding in Europe. In: Region (2021) No 8(2), p. 57-81. doi:10.18335/region.v8i2.352CitationDetails
  • E, Goetjes; M, Pavlova; C, Hongoro; W, Groot: Socioeconomic Inequalities and Obesity in South Africa—A Decomposition Analysis.. In: International Journal of Environmental Research and Public Health, Vol 2021 (2021). doi:10.3390/ijerph18179181CitationDetails
  • Avdic D, Blankart KE: Do soft cost-control measures change productivity? - Preferred statin prescribing in Germany. 2021. doi:10.5465/AMBPP.2021.226CitationDetails
  • K E, Blankart; F R, Lichtenberg: Are patients more adherent to newer drugs?. In: Health Care Management Science, Vol 2020 (2020). doi:10.1007/s10729-020-09513-5CitationDetails
  • K E, Blankart; T, Stargardt: The impact of drug quality ratings from health technology assessments on the adoption of new drugs by physicians in Germany. In: Health Economics, Vol 2020 (2020). Full textCitationDetails
  • K E, Blankart; F, Arndt: Physician-Level Cost Control Measures and Regional Variation of Biosimilar Utilization in Germany. In: International Journal of Environmental Research and Public Health, Vol 2020 (2020) No 17. doi:10.3390/ijerph17114113CitationDetails
  • V, Winter; M K, Thomsen; J, Schreyögg; K E, Blankart; L, Duminy; L, Schoeneberger; J P, Ansah; D, Matchar; C R, Blankart; E, Oppel; U T, Jensen: Improving Service Provision - The Health Care Services’ Perspective. In: Journal of Service Management Research (2019) No 3(4), p. 163-183. Full textCitationDetails
  • A, Angerer; T, Brand; S, Berger: Same Same But Different – A Literature Review on the Lean Improvement Concepts in Operating Rooms Settings, EURAM Annual Conference. Lisbon 2019. Full textCitationDetails
  • M S, Kurte; K E, Blankart: Ambulant-sensitive Krankenhausfälle in Deutschland – Abgrenzung, Prävalenz und Kosten. In: Gesundheitsökonomie & Qualitätsmanagement, Vol 2019 (2019). doi:10.1055/a-0890-9600Full textCitationDetails
  • D, Guhl; K E, Blankart; T, Stargardt: Service quality and perceived customer value in community pharmacies. In: Health Services Management Research (2019) No 32(1), p. 36-48. doi:10.1177/0951484818761730Full textCitationDetails
  • T, Brand; A, Angerer; S, Schmelzer: Like a Swiss Watch? Measuring the Effects of a Lean Implementation at Bern University Hospital, IRSPM Conference. Wellington 2019. Full textCitationDetails
  • J, Schätzle; K, Homayounfar; H, Räwer; T, Brand; S, Kriech; A, Angerer; J, Lindenmeier; F, Liberatore: Preferences of Senior Physicians for Management Responsibilities in German University Hospitals. 1. Proceedings, Academy Of Management (Ed.), 2018. doi:10.5465/AMBPP.2018.15996abstractCitationDetails
  • J, Schätzle; K, Homayounfar; H, Räwer; T, Brand; S, Kriech; A, Angerer; J, Lindenmeier; F, Liberatore: Physicians as Jacks of All Trades? Preferences of Senior Physicians for Accepting Management Responsibilities in German University Hospitals – An Application of the EPL Framework, EURAM Annual Conference. Reykjavik 2018. Full textCitationDetails
  • V D, Lauenroth; K E, Blankart; T, Stargardt: Stakeholder Participation in Regulatory Decision-Making. 11748. Proceedings, Academy Of Management (Ed.), 2018. Full textCitationDetails
  • A, Angerer; S, Schmidt; T, Brand; F, Liberatore: Getting the Two to Dance - How Intra-Organizational Readiness Fosters Collaboration Quality between Hospitals and Health Insurance Providers. In: American Journal of Management , Vol 18 (2018) No 1, p. 108-122. Full textCitationDetails
  • K E, Fischer; T, Koch; K, Kostev; T, Stargardt: The impact of physician-level drug budgets on prescribing behaviour. In: European Journal of Health Economics, Vol 19 (2017) No 2, p. 213-222. doi:10.1007/s10198-017-0875-9Full textCitationDetails
  • K E, Fischer; K, Peters; T, Stargardt: Information on product quality, change agency and product adoption. 13580. Proceedings, Academy Of Management (Ed.), 2017. Full textCitationDetails
  • K E, Fischer; T, Stargardt: The diffusion of generics after patent expiry in Germany. In: European Journal of Health Economics, Vol 17 (2016) No 8, p. 1027-1040. doi:10.1007/s10198-015-0744-3CitationDetails
  • G, Hostenkamp; K E, Fischer; K, Borch-Johnsen: Drug safety and the impact of drug warnings: An interrupted time series analysis of diabetes drug prescriptions in Germany and Denmark. In: Health Policy, Vol 120 (2016) No 12, p. 1404-1411. doi:10.1016/j.healthpol.2016.09.020CitationDetails
  • A, Angerer; F, Liberatore; T, Brand: Still Lost in Transformation? A Literature Review on the Scientific Support of Lean Health Care Transformations, EURAM Annual Conference. Paris 2016. Full textCitationDetails
  • K E, Fischer; T, Heisser; T, Stargardt: Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia. In: Health Policy, Vol 120 (2016) No 10, p. 1115-1122. doi:10.1016/j.healthpol.2016.08.001CitationDetails
  • T, Brand; F, Liberatore; E, Hollenstein; A, Angerer: Spread the Word: A Replication and Theoretical Extension of a Word-of-Mouth Model of Consumer Behavior with Regard to the Context of HIV Prevention Campaigns, IRSPM Conference. Hong Kong 2016. Full textCitationDetails
  • D, Guhl; T, Stargardt; U, Schneider; K E, Fischer: Dispensing behaviour of pharmacies in prescription drug markets. In: Health Policy, Vol 120 (2016) No 2, p. 190-197. doi:10.1016/j.healthpol.2016.01.010CitationDetails
  • K E, Fischer; R, Leidl: Analysing coverage decision-making: opening Pandora’s box?. In: Eur J Health Econ, Vol 15 (2014) No 9, p. 889-906. doi:10.1007/s10198-014-0566-8CitationDetails
  • K E, Fischer; T, Stargardt: Early Benefit Assessment of Pharmaceuticals in Germany Manufacturers’ Expectations versus the Federal Joint Committee’s Decisions. In: Med Decis Making, Vol 34 (2014) No 8, p. 1030-1047. doi:10.1177/0272989X14546377CitationDetails
  • K E, Fischer; W H, Rogowski: Funding Decisions for Newborn Screening: A Comparative Review of 22 Decision Processes in Europe. In: International Journal of Environmental Research and Public Health, Vol 11 (2014) No 5, p. 5403-5430. doi:10.3390/ijerph110505403CitationDetails
  • K E, Fischer; W H, Rogowski; R, Leidl; B, Stollenwerk: Transparency vs. closed-door policy: Do process characteristics have an impact on the outcomes of coverage decisions? A statistical analysis. In: Health Policy, Vol 112 (2013) No 3, p. 187-196. doi:10.1016/j.healthpol.2013.04.011CitationDetails
  • K E, Fischer; B, Stollenwerk; W H, Rogowski: Link between Process and Appraisal in Coverage decisions: An Analysis with Structural Equation Modeling. In: Medical Decision Making, Vol 33 (2013) No 8, p. 1009-1025. doi:10.1177/0272989X13490837CitationDetails
  • K E, Fischer: Ansätze zur empirischen Analyse von Entscheidungen über die Erstattungsfähigkeit von Gesundheitstechnologien in industrialisierten Ländern. In: RPG Recht und Politik im Gesundheitswesen, Vol 19 (2013) No 3, p. 67-81. CitationDetails
  • K E, Fischer: A systematic review of coverage decision-making on health technologies—Evidence from the real world. In: Health Policy, Vol 107 (2012) No 2-3, p. 218-230. doi:10.1016/j.healthpol.2012.07.005CitationDetails
  • K E, Fischer: Decision-making in healthcare: a practical application of partial least square path modelling to coverage of newborn screening programmes. In: BMC Medical Informatics and Decision Making, Vol 12 (2012) No 1, p. 83. doi:10.1186/1472-6947-12-83CitationDetails
  • K E, Fischer; S D, Grosse; W H, Rogowski: The role of health technology assessment in coverage decisions on newborn screening. In: International Journal of Technology Assessment in Health Care, Vol 27 (2011) No 04, p. 313-321. doi:10.1017/S0266462311000468CitationDetails
  • K E, Fischer; R, Leidl; W H, Rogowski: A structured tool to analyse coverage decisions: Development and feasibility test in the field of cancer screening and prevention. In: Health Policy, Vol 101 (2011) No 3, p. 290-299. doi:10.1016/j.healthpol.2011.03.002CitationDetails